Technical Analysis for CUE - Cue Biopharma, Inc.

Grade Last Price % Change Price Change
grade B 7.55 -6.44% -0.52
CUE closed down 6.44 percent on Friday, August 23, 2019, on 72 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical CUE trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction -6.44%
Narrow Range Bar Range Contraction -6.44%
NR7 Range Contraction -6.44%

Older signals for CUE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Health Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Medication Pharmacy Cancers Specialty Drugs Autoimmunity Autoimmune Disorders
Is CUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 26 Canaccord likes CRISPR Therapeutics in today's analyst action
Jul 12 Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?
Jun 3 Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference
May 16 FDA accepts Cue Bio's IND for CUE-101; shares up 5% premarket
May 16 Cue Biopharma to Host Business Update Call and Webcast
May 16 Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers
May 9 Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference
Apr 29 If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today
Apr 8 Cue Biopharma to Present Immuno-STAT Platform Technology at PEGs Boston 2019
Mar 18 48 Stocks Moving In Monday's Mid-Day Session
See more CUE news...
Indicators
Indicator Value
52 Week High 9.94
52 Week Low 4.16
Average Volume 102,777
200-Day Moving Average 7.027
50-Day Moving Average 7.716
20-Day Moving Average 7.932
10-Day Moving Average 7.94
Average True Range 0.5079
ADX 13.22
+DI 21.3183
-DI 23.5083
Chandelier Exit (Long, 3 ATRs ) 7.1463
Chandelier Exit (Short, 3 ATRs ) 8.2637
Upper Bollinger Band 8.489
Lower Bollinger Band 7.375
Percent B (%b) 0.16
BandWidth 14.044377
MACD Line 0.0743
MACD Signal Line 0.0869
MACD Histogram -0.0126
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.54
Resistance 3 (R3) 8.59 8.30 8.38
Resistance 2 (R2) 8.30 8.05 8.28 8.32
Resistance 1 (R1) 7.93 7.90 7.79 7.88 8.26
Pivot Point 7.64 7.64 7.57 7.62 7.64
Support 1 (S1) 7.27 7.39 7.13 7.22 6.84
Support 2 (S2) 6.98 7.24 6.96 6.78
Support 3 (S3) 6.61 6.98 6.73
Support 4 (S4) 6.56